Up to date therapies such as glucagon like peptide 1 receptor agonist (GLP-1) are increasingly being used in the treatment of T2DM
However, to achieve long-term results, care providers have found that the best outcomes are achieved when the medication is paired with a medically supervised wellness program that fits your lifestyle
Gastrointestinal Changes Nausea, vomiting, diarrhea, and constipation are the most common reports
& Zhang, N
We have reviewed the failures of previous clinical candidates, outlining an updated set of criteria that define successful melanocortin agonists for obesity: high potency, preferred selectivity profiles, PK exposures that enable central penetrance, and clean cardiac safety profiles
Your clinician usually reviews trends over time before making any treatment changes